Methylphenidate
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Methylphenidate: From ADHD to Faciodigitogenital Syndrome
One-Sentence Summary
Methylphenidate is a dopamine/norepinephrine reuptake inhibitor widely known as a stimulant used for ADHD, though this evidence pack contains no formal license or indication record for it. The TxGNN model’s top-ranked prediction is Faciodigitogenital Syndrome (Aarskog syndrome, an X-linked congenital developmental disorder), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph link with no mechanistic or empirical backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from license data (0 licenses on file); methylphenidate is generally known as an ADHD stimulant, but original indication/MOA data for this pack is a data gap |
| Predicted New Indication | Faciodigitogenital Syndrome (Aarskog syndrome) |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap). Based on general knowledge, methylphenidate is a central nervous system stimulant that inhibits dopamine and norepinephrine reuptake, and it is best known as a treatment for ADHD.
Faciodigitogenital syndrome (Aarskog syndrome) is an X-linked genetic developmental disorder affecting facial, digital, and genital morphology, caused by mutations unrelated to catecholaminergic signaling. There is no known pathophysiological overlap between a monoamine reuptake inhibitor and a structural/genetic developmental syndrome.
The evidence pack itself states this directly: the mechanistic link is unverifiable, and the high TxGNN score (rank 147 of the model’s overall output) reflects only a graph-embedding association, not any clinical or biological plausibility. This candidate should be treated as a low-confidence model artifact rather than a genuine repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No marketing authorization records are on file for this drug in this dataset (0 licenses, market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction carries the highest TxGNN score among this drug’s candidates but has zero supporting clinical trials or literature and no plausible mechanistic connection between methylphenidate’s catecholaminergic action and a genetic developmental syndrome. This is a model-only (L5) signal and does not meet the threshold to advance.
To proceed, the following is needed:
- TFDA label warnings/contraindications data (currently blocking — DG001)
- Confirmed mechanism of action (MOA) data from DrugBank (DG002)
- Any preclinical or case-level evidence specifically linking methylphenidate to Aarskog syndrome, before further evaluation is warranted
- Note: this drug’s rank-3 candidate (“specific developmental disorder,” L2/S2, Proceed with Guardrails) has substantially stronger clinical and literature support and may warrant a separate, higher-priority evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.